171 related articles for article (PubMed ID: 25266282)
1. Potential avoidance of adverse analgesic effects using a biologically "smart" hydrogel capable of controlled bupivacaine release.
Taraballi F; Minardi S; Corradetti B; Yazdi IK; Balliano MA; Van Eps JL; Allegri M; Tasciotti E
J Pharm Sci; 2014 Nov; 103(11):3724-3732. PubMed ID: 25266282
[TBL] [Abstract][Full Text] [Related]
2. Bupivacaine-loaded biodegradable poly(lactic-co-glycolic) acid microspheres I. Optimization of the drug incorporation into the polymer matrix and modelling of drug release.
Zhang H; Lu Y; Zhang G; Gao S; Sun D; Zhong Y
Int J Pharm; 2008 Mar; 351(1-2):244-9. PubMed ID: 18024022
[TBL] [Abstract][Full Text] [Related]
3. Characterization of rabies pDNA nanoparticulate vaccine in poloxamer 407 gel.
Bansal A; Wu X; Olson V; D'Souza MJ
Int J Pharm; 2018 Jul; 545(1-2):318-328. PubMed ID: 29746999
[TBL] [Abstract][Full Text] [Related]
4. Preparation, characterization and in vitro cytotoxicity of indomethacin-loaded PLLA/PLGA microparticles using supercritical CO2 technique.
Kang Y; Wu J; Yin G; Huang Z; Yao Y; Liao X; Chen A; Pu X; Liao L
Eur J Pharm Biopharm; 2008 Sep; 70(1):85-97. PubMed ID: 18495445
[TBL] [Abstract][Full Text] [Related]
5. Spatiotemporal Programing for the On-Demand Release of Bupivacaine Based on an Injectable Composite Hydrogel.
Dinh VV; Suh YS; Yang HK; Lim YT
J Pharm Sci; 2016 Dec; 105(12):3634-3644. PubMed ID: 27789030
[TBL] [Abstract][Full Text] [Related]
6. Local anesthetic effects of bupivacaine loaded lipid-polymer hybrid nanoparticles: In vitro and in vivo evaluation.
Ma P; Li T; Xing H; Wang S; Sun Y; Sheng X; Wang K
Biomed Pharmacother; 2017 May; 89():689-695. PubMed ID: 28267672
[TBL] [Abstract][Full Text] [Related]
7. PLGA microparticle-embedded thermosensitive hydrogels for sustained release of hydrophobic drugs.
Joung YK; Choi JH; Park KM; Park KD
Biomed Mater; 2007 Dec; 2(4):269-73. PubMed ID: 18458485
[TBL] [Abstract][Full Text] [Related]
8. Tracking the in vivo release of bioactive NRG from PLGA and PEG-PLGA microparticles in infarcted hearts.
Pascual-Gil S; Simón-Yarza T; Garbayo E; Prosper F; Blanco-Prieto MJ
J Control Release; 2015 Dec; 220(Pt A):388-396. PubMed ID: 26546270
[TBL] [Abstract][Full Text] [Related]
9. Design and optimization of NSAID loaded nanoparticles.
Sashmal S; Mukherjee S; Ray S; Thakur RS; Ghosh LK; Gupta BK
Pak J Pharm Sci; 2007 Apr; 20(2):157-62. PubMed ID: 17416573
[TBL] [Abstract][Full Text] [Related]
10. PLGA:poloxamer blend micro- and nanoparticles as controlled release systems for synthetic proangiogenic factors.
Parajó Y; d'Angelo I; Horváth A; Vantus T; György K; Welle A; Garcia-Fuentes M; Alonso MJ
Eur J Pharm Sci; 2010 Dec; 41(5):644-9. PubMed ID: 20869438
[TBL] [Abstract][Full Text] [Related]
11. Silicon microfluidic flow focusing devices for the production of size-controlled PLGA based drug loaded microparticles.
Keohane K; Brennan D; Galvin P; Griffin BT
Int J Pharm; 2014 Jun; 467(1-2):60-9. PubMed ID: 24680950
[TBL] [Abstract][Full Text] [Related]
12. Compared in vivo toxicity in mice of lung delivered biodegradable and non-biodegradable nanoparticles.
Aragao-Santiago L; Hillaireau H; Grabowski N; Mura S; Nascimento TL; Dufort S; Coll JL; Tsapis N; Fattal E
Nanotoxicology; 2016; 10(3):292-302. PubMed ID: 26573338
[TBL] [Abstract][Full Text] [Related]
13. Surface-functionalized, pH-responsive poly(lactic-co-glycolic acid)-based microparticles for intranasal vaccine delivery: Effect of surface modification with chitosan and mannan.
Li Z; Xiong F; He J; Dai X; Wang G
Eur J Pharm Biopharm; 2016 Dec; 109():24-34. PubMed ID: 27569030
[TBL] [Abstract][Full Text] [Related]
14. Sustainable release of vancomycin, gentamicin and lidocaine from novel electrospun sandwich-structured PLGA/collagen nanofibrous membranes.
Chen DW; Hsu YH; Liao JY; Liu SJ; Chen JK; Ueng SW
Int J Pharm; 2012 Jul; 430(1-2):335-41. PubMed ID: 22521880
[TBL] [Abstract][Full Text] [Related]
15. A Novel Method for Preparing Surface-Modified Fluocinolone Acetonide Loaded PLGA Nanoparticles for Ocular Use: In Vitro and In Vivo Evaluations.
Salama AH; Mahmoud AA; Kamel R
AAPS PharmSciTech; 2016 Oct; 17(5):1159-72. PubMed ID: 26589410
[TBL] [Abstract][Full Text] [Related]
16. Unintended potential impact of perfect sink conditions on PLGA degradation in microparticles.
Klose D; Delplace C; Siepmann J
Int J Pharm; 2011 Feb; 404(1-2):75-82. PubMed ID: 21056644
[TBL] [Abstract][Full Text] [Related]
17. Sciatic nerve blockade with lipid-protein-sugar particles containing bupivacaine.
Kohane DS; Lipp M; Kinney RC; Lotan N; Langer R
Pharm Res; 2000 Oct; 17(10):1243-9. PubMed ID: 11145230
[TBL] [Abstract][Full Text] [Related]
18. Inhalable DNase I microparticles engineered with biologically active excipients.
Osman R; Al Jamal KT; Kan PL; Awad G; Mortada N; El-Shamy AE; Alpar O
Pulm Pharmacol Ther; 2013 Dec; 26(6):700-9. PubMed ID: 23933140
[TBL] [Abstract][Full Text] [Related]
19. Release of rifampicin from chitosan, PLGA and chitosan-coated PLGA microparticles.
Manca ML; Loy G; Zaru M; Fadda AM; Antimisiaris SG
Colloids Surf B Biointerfaces; 2008 Dec; 67(2):166-70. PubMed ID: 18835764
[TBL] [Abstract][Full Text] [Related]
20. Preparation and in vitro evaluation of etoposide-loaded PLGA microspheres for pulmonary drug delivery.
Feng R; Zhang Z; Li Z; Huang G
Drug Deliv; 2014 May; 21(3):185-92. PubMed ID: 24107001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
